Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 7Terminated 4Unknown 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thromboembolism 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 129Radiotherapy 94Carboplatin 82Fluorouracil 77Paclitaxel 76Cyclophosphamide 76Gemcitabine 71Capecitabine 66Docetaxel 64Doxorubicin 59Oxaliplatin 57Etoposide 57Leucovorin 48Vincristine 46Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Pemetrexed 27Neoadjuvant Therapy 26Irinotecan 25Tamoxifen 24Prednisone 23Methotrexate 21Rituximab 19Vinorelbine 18Radiotherapy, Intensity-Modulated 18Peripheral Blood Stem Cell Transplantation 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Dalteparin × Clear all
NCT00519805 2011-08-08

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
2,200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡